Public distrusts pharma on cancer drive; Perrigo drops nice surprise on Street; FDA approves Doxil generic

@FiercePharma: U.S. government finally gets payment rule published. News | Follow @FiercePharma

@EricPFierce: AstraZeneca, Bristol-Myers Squibb create 'Diabetes Inc.,' to give complete attention to diabetes treatment sales. More | Follow @EricPFierce

@AlisonBFierce: A study of the first new TB vaccine in 90 years showed it offered no added benefit to the current vaccine. News | Follow @AlisonBFierce

> A Lilly Oncology-sponsored survey found that 60% of respondents think drugmakers would rather make money treating cancer and than find ways to cure it. Story

> The GAVI global vaccines group will pay to help vaccinate about 180,000 girls in Africa and Asia against cervical cancer with vaccines from Merck ($MRK) and GlaxoSmithKline ($GSK). Story

> The FDA has approved Hyperion Therapeutics' ($HPTX) Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older. Story

> The House Energy and Commerce Committee has given the FDA until Feb. 25 to provide all the documents on New England Compounding Center, which is tied to a nationwide meningitis outbreak, or face a subpoena. Item

> The government in India is creating three more branches of the Delhi State Cancer Institute to serve more patients. Story

> The FDA says it has approved first generic of J&J cancer drug Doxil from Sun Pharma to help end shortage. Release

Medical Device News

 @FierceMedDev: Swiss team: Nanoscale tissue check boosts breast cancer Dx. More | Follow @FierceMedDev

 @MarkHFierce: GE and the N.F.L. will jointly develop new imaging tech to spot concussions. News| Follow @MarkHFierce

 @DamianFierce: Icon is spending $52M on Cross Country Healthcare's clinical trials business. Report | Follow @DamianFierce

> AdvaMed targets Puerto Rico device tax hike as unfair burden. News

> Covidien ticks toward pharma spinoff. Article

> Yogurt, pacemakers compel conflict-of-interest issues in Florida. Item

Biotech News

 @FierceBiotech: Popular this weekend: Merck R&D calls for a time-out on osteo blockbuster hopeful. Story | Follow @FierceBiotech

@JohnCFierce: Interesting to see Medicines Co. pay Alnylam $25M upfront for early-stage PCSK9 program. More | Follow @JohnCFierce

@RyanMFierce: $GILD says SVR 67% in oral combo is same as SVR on interferon group in Ph3 FISSION study in hep C types 2&3, meets primary endpoint. Release | Follow @RyanMFierce

> Bitter setback as TB vaccine fails to protect infants in key study. News

> Rockwell shares surge as PhIII iron deficiency study offers upbeat outcomes. Report

> Alnylam licenses away hot PCSK9 prospect in 'small' $205M deal. Story

CRO News

> Parexel brightens 2013 outlook after strong quarter. Story

> BioClinica eyed for $123M buyout, eventual merger. News

> Indian clinical trials: Private group steps in to increase transparency. More

> Patheon brings bioavailability service to EU with plant expansion. Report

Biotech IT News

> Cypher Genomics chief speaks out from DNA data-crunching crowd. Story

> Clinical trials software player agrees to $123M buyout. News

> Boehringer unleashes iPhone app amid COPD blitz. Report

> Biopharma targets bioinformatics aces in R&D overhaul. Article

And Finally...The rapidly-growing Perrigo ($PRGO) announced earnings today which were enhanced by recent acquisitions and exceeded expectations on the Street. Story
 

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.